AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30265304 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF/ICSI children
Number of subjects: 72
Study 30265304 — intervention group
Group type: EXPERIMENTAL
Intervention: NC children
Number of subjects: 72
Study 30265679 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF pod-IVR
Number of subjects: 6
Study 30265679 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF-FTC pod-IVR
Number of subjects: 6
Study 30265679 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF-FTC-MVC pod-IVR
Number of subjects: 6
Study 30266081 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT)
Number of subjects: 600
Study 30266081 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory biomarkers
Number of subjects: 600
Study 30266081 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical features (cancer type, performance status, pain intensity)
Number of subjects: 600
Study 30266081 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic data and clinical variables
Number of subjects: 600
Study 30266081 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal relationship between pain intensity and depression
Number of subjects: 600
Study 30266081 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors for development of cachexia
Number of subjects: 600
Study 30266716 — intervention group
Group type: EXPERIMENTAL
Intervention: High menstrual restriction (two or more types)
Number of subjects: 1800
Study 30266716 — intervention group
Group type: COMPARATOR
Intervention: Demographic variables and IPV
Number of subjects: 1800
Study 30267153 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm water immersion (WWI) at 33-35 °C
Number of subjects: 17
Study 30267377 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 7511
Study 30267377 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 7511
Study 30267377 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 7511
Study 30267561 — intervention group
Group type: EXPERIMENTAL
Intervention: European Society for Radiotherapy and Oncology (ESTRO) contouring guidelines
Number of subjects: 0
Study 30267561 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation Therapy Oncology Group (RTOG) contouring guidelines
Number of subjects: 0
Study 30267561 — intervention group
Group type: EXPERIMENTAL
Intervention: TROG 12.02 PET LABRADOR trial guidelines
Number of subjects: 0
Study 30267561 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton/Photon trial NCT02603341 RADCOMP guidelines
Number of subjects: 0
Study 30267561 — intervention group
Group type: COMPARATOR
Intervention: Mapping recurrence patterns studies
Number of subjects: 0
Study 30267941 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive perampanel ≤12 mg/day during a 10-week treatment period (Study 231)
Number of subjects: 30
Study 30267941 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive perampanel
Number of subjects: 30
Study 30268101 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem alcohol use
Number of subjects: 438
Study 30268101 — intervention group
Group type: COMPARATOR
Intervention: First line TB therapy
Number of subjects: 438
Study 30268146 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic shock patients
Number of subjects: 96
Study 30268146 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-survivors of septic shock
Number of subjects: 96
Study 30268146 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors of septic shock
Number of subjects: 96
Study 30268146 — intervention group
Group type: COMPARATOR
Intervention: Non-infected controls
Number of subjects: 96
Study 30268483 — intervention group
Group type: EXPERIMENTAL
Intervention: lumretuzumab (monoclonal anti-HER3 antibody) in combination with erlotinib
Number of subjects: 2
Study 30268833 — intervention group
Group type: EXPERIMENTAL
Intervention: rHVPG (radiomics model)
Number of subjects: 385
Study 30269047 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild OSA
Number of subjects: 355
Study 30269047 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-severe OSA
Number of subjects: 355
Study 30269047 — intervention group
Group type: COMPARATOR
Intervention: Primary Snorers (PS)
Number of subjects: 355
Study 30269047 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 355
Study 30269047 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI z score
Number of subjects: 355
Study 30269047 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen saturation nadir
Number of subjects: 355
Study 30269047 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen desaturation index (ODI)
Number of subjects: 355
Study 30269072 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners (GPs) in out-of-hours care
Number of subjects: 23
Study 30269072 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners (GPs) and pharmacists
Number of subjects: 23
Study 30269072 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour change interventions
Number of subjects: 23
Study 30269073 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led monitoring using the structured adverse drug reaction (ADRe) profile
Number of subjects: 0
Study 30269264 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphologic manifestations
Number of subjects: 472
Study 30269264 — intervention group
Group type: EXPERIMENTAL
Intervention: Snoring syndrome
Number of subjects: 472
Study 30269264 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthenia
Number of subjects: 472
Study 30269264 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrepancy rates between patient- and physician-reported manifestations
Number of subjects: 472
Study 30269264 — intervention group
Group type: EXPERIMENTAL
Intervention: Earliest manifestations prior to diagnosis
Number of subjects: 472
Study 30269346 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-life therapeutic intervention for psoriasis
Number of subjects: 143
Study 30269827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ostial CTO PCI
Number of subjects: 971
Study 30269827 — intervention group
Group type: COMPARATOR
Intervention: Nonostial CTO PCI
Number of subjects: 971
Study 30269918 — intervention group
Group type: EXPERIMENTAL
Intervention: Td vaccination (group-1)
Number of subjects: 3
Study 30269918 — intervention group
Group type: EXPERIMENTAL
Intervention: Td vaccination (group-2)
Number of subjects: 3
Study 30269918 — intervention group
Group type: EXPERIMENTAL
Intervention: Td vaccination (group-1 and group-2)
Number of subjects: 3
Study 30270406 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem-vaborbactam (2 g/2 g over 3 h, q8h for 7-14 days)
Number of subjects: 77
Study 30270406 — intervention group
Group type: COMPARATOR
Intervention: Best Available Therapy (BAT)
Number of subjects: 77
Study 30270433 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 73
Study 30270433 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted version of the Maudsley Staging Method (MSM)
Number of subjects: 73
Study 30271122 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoinjector
Number of subjects: 179
Study 30271122 — intervention group
Group type: COMPARATOR
Intervention: Prefilled syringe
Number of subjects: 179
Study 30271122 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 179
Study 30271191 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (40-60 mg/day)
Number of subjects: 303
Study 30271191 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin (300-600 mg/day)
Number of subjects: 303
Study 30271191 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine and Pregabalin
Number of subjects: 303
Study 30271433 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedical Coaching (TMC)
Number of subjects: 180
Study 30271433 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedical (TM)
Number of subjects: 180
Study 30271433 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study 30271433 — intervention group
Group type: COMPARATOR
Intervention: TMC compared to Control group
Number of subjects: 180
Study 30271433 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC
Number of subjects: 180
Study 30271882 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial plasma resuscitation
Number of subjects: 0
Study 30271882 — intervention group
Group type: COMPARATOR
Intervention: Balanced crystalloid (BC) resuscitation
Number of subjects: 0
Study 30272177 — intervention group
Group type: EXPERIMENTAL
Intervention: STarT Back risk-stratified care model
Number of subjects: 0
Study 30272177 — intervention group
Group type: EXPERIMENTAL
Intervention: STarT Back tool
Number of subjects: 0
Study 30272836 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based counseling plus community-situated physical activity (PA) for 12 months in BC survivors.
Number of subjects: 48
Study 30272836 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based counseling plus community-situated physical activity (PA) for 12 months in CRC survivors.
Number of subjects: 48
Study 30273231 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty (TKA) surgery
Number of subjects: 133
Study 30273231 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgery peers
Number of subjects: 133
Study 30273269 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuraxial anesthesia
Number of subjects: 107317
Study 30273450 — intervention group
Group type: COMPARATOR
Intervention: Visual exploration task using eye-tracking technology
Number of subjects: 129
Study 30273450 — intervention group
Group type: COMPARATOR
Intervention: Recurrent quantification analysis
Number of subjects: 129
Study 30273531 — intervention group
Group type: EXPERIMENTAL
Intervention: Crude incidence rate of VTE for clinical patients
Number of subjects: 0
Study 30273531 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted incidence rate of VTE for clinical patients
Number of subjects: 0
Study 30273531 — intervention group
Group type: EXPERIMENTAL
Intervention: Crude incidence rate of VTE for surgical patients
Number of subjects: 0
Study 30273531 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted incidence rate of VTE for surgical patients
Number of subjects: 0
Study 30273531 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence rate ratio (IRR) for VTE
Number of subjects: 0
Study 30273708 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit Body and Soul (FBAS)
Number of subjects: 604
Study 30273708 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 604
Study 30273841 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Number of subjects: 1000
Study 30274768 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended cardiac monitoring using 2 24-hour Holter monitors followed by a Medtronic Reveal XT implantable loop recorder if no AF detected.
Number of subjects: 25
Study 30274768 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure therapy (CPAP) used by 96% of patients with 68% total adherence.
Number of subjects: 25
Study 30274964 — intervention group
Group type: EXPERIMENTAL
Intervention: Twitter monitoring intervention for recruitment in cancer trials
Number of subjects: 84
Study 30274965 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy for breast cancer
Number of subjects: 250
Study 30274980 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched treatment based on genomic profile
Number of subjects: 591
Study 30274985 — intervention group
Group type: EXPERIMENTAL
Intervention: Avapritinib
Number of subjects: 0
Study 30275092 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Plazomicin
Number of subjects: 24
Study 30275886 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate treatment
Number of subjects: 188
Study 30275966 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-based caregiver engagement strategies (texting and social media)
Number of subjects: 0
Study 30275966 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component childhood obesity prevention intervention
Number of subjects: 0
Study 30276205 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-printed personalized guides
Number of subjects: 29
Study 30276205 — intervention group
Group type: COMPARATOR
Intervention: Traditional method (control)
Number of subjects: 29
Study 30276473 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional talk during the second review session
Number of subjects: 60
Study 30276473 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of space by the therapeutic radiographer (TR) during the second session
Number of subjects: 60
Study 30276654 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians
Number of subjects: 10284
Study 30276654 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced Practice Clinicians (APCs)
Number of subjects: 10284
Study 30276654 — intervention group
Group type: COMPARATOR
Intervention: Non-solo practice (2-5 physician/APCs)
Number of subjects: 10284
Study 30276654 — intervention group
Group type: COMPARATOR
Intervention: Health system affiliation
Number of subjects: 10284
Study 30276654 — intervention group
Group type: COMPARATOR
Intervention: Federally Qualified Health Center status
Number of subjects: 10284
Study 30276654 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in an accountable care organization
Number of subjects: 10284
Study 30277031 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor-initiated or self-paced intervention promoting daily self-weighing
Number of subjects: 248
Study 30277089 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (target 25mg daily) plus dexamethasone for 18 cycles
Number of subjects: 31
Study 30277094 — intervention group
Group type: EXPERIMENTAL
Intervention: Plecanatide, dosage and duration not specified
Number of subjects: 0
Study 30278056 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training for 12 weeks
Number of subjects: 24
Study 30278056 — intervention group
Group type: COMPARATOR
Intervention: Control (no resistance training)
Number of subjects: 24
Study 30278378 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 30 mg/day plus cetuximab 250 mg/m2
Number of subjects: 0
Study 30279111 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA next-generation sequencing
Number of subjects: 77
Study 30279125 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivacaftor (VX-770)
Number of subjects: 117
Study 30279583 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate HistoScanning (PHS)
Number of subjects: 330
Study 30279583 — intervention group
Group type: EXPERIMENTAL
Intervention: PHS-targeted biopsies
Number of subjects: 330
Study 30280516 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 523
Study 30280516 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucoma patients
Number of subjects: 523
Study 30280586 — intervention group
Group type: EXPERIMENTAL
Intervention: ChonDux hydrogel scaffold implantation in combination with microfracture
Number of subjects: 18
Study 30280649 — intervention group
Group type: EXPERIMENTAL
Intervention: Treovance stent-graft
Number of subjects: 202
Study 30280905 — intervention group
Group type: EXPERIMENTAL
Intervention: AD+HIV (treatment-naive HIV diagnosis)
Number of subjects: 14
Study 30280905 — intervention group
Group type: COMPARATOR
Intervention: AD (without HIV infection)
Number of subjects: 14
Study 30280906 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline 25-hydroxy vitamin D <20 ng/mL
Number of subjects: 101
Study 30280906 — intervention group
Group type: EXPERIMENTAL
Intervention: Black race
Number of subjects: 101
Study 30280906 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxy vitamin D ≥20 and tenofovir diphosphate (TFV-DP) >700 fmol/punch
Number of subjects: 101
Study 30280906 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxy vitamin D <20 and TFV-DP ≤700
Number of subjects: 101
Study 30280906 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxy vitamin D <20 and TFV-DP >700
Number of subjects: 101
Study 30280906 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective TFV-DP concentrations (>700 fmol/punch)
Number of subjects: 101
Study 30281207 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-acute physical therapy interventions
Number of subjects: 112
Study 30281207 — intervention group
Group type: EXPERIMENTAL
Intervention: Open chain exercises
Number of subjects: 112
Study 30281207 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed chain exercises
Number of subjects: 112
Study 30281677 — intervention group
Group type: EXPERIMENTAL
Intervention: Indicators of economic provision for men
Number of subjects: 1357
Study 30281677 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity for women
Number of subjects: 1357
Study 30281677 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity and childhood traumas
Number of subjects: 1357
Study 30281677 — intervention group
Group type: EXPERIMENTAL
Intervention: More education
Number of subjects: 1357
Study 30281677 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions to reduce household food insecurity
Number of subjects: 1357
Study 30281677 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions focusing on mental health and substance misuse
Number of subjects: 1357
Study 30281677 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing educational attainment
Number of subjects: 1357
Study 30281992 — intervention group
Group type: EXPERIMENTAL
Intervention: High acceleration in annual BMI increments during preschool years
Number of subjects: 51905
Study 30281992 — intervention group
Group type: EXPERIMENTAL
Intervention: Being large for gestational age at birth
Number of subjects: 51905
Study 30281992 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity at 3 years of age
Number of subjects: 51905
Study 30281992 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual BMI increments between 2 and 6 years of age
Number of subjects: 51905
Study 30282468 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Monitoring (HBPM) with phone-based coaching on technique and sharing findings; mean HBPM systolic blood pressure (SBP) values were ⩾135 mm Hg; assessed over 12 months.
Number of subjects: 217
Study 30282468 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Monitoring (HBPM) users; racial comparison of treatment intensification.
Number of subjects: 217
Study 30282468 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Monitoring (HBPM) users; gender comparison of treatment intensification.
Number of subjects: 217
Study 30282468 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Monitoring (HBPM) users; racial comparison of SBP reduction after intensification.
Number of subjects: 217
Study 30282622 — intervention group
Group type: EXPERIMENTAL
Intervention: USSD tool for real-time safety data collection
Number of subjects: 0
Study 30282622 — intervention group
Group type: COMPARATOR
Intervention: Hardcopy tool for safety data collection
Number of subjects: 0
Study 30282640 — intervention group
Group type: EXPERIMENTAL
Intervention: Fabry disease patients (FD)
Number of subjects: 221
Study 30282640 — intervention group
Group type: EXPERIMENTAL
Intervention: LVH-negative FD patients (early disease)
Number of subjects: 221
Study 30282673 — intervention group
Group type: EXPERIMENTAL
Intervention: GFC/LT
Number of subjects: 30
Study 30282673 — intervention group
Group type: COMPARATOR
Intervention: ROTEM (EXTEM ML)
Number of subjects: 30
Study 30282673 — intervention group
Group type: COMPARATOR
Intervention: ECLT
Number of subjects: 30
Study 30282677 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled loxapine (ADASUVE) 10 mg self-administered
Number of subjects: 500
Study 30282826 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldesleukin (recombinant human IL-2) at a dose of 0.26 × 106 IU/m2 every 3 days
Number of subjects: 38
Study 30282826 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 38
Study 30282826 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldesleukin (recombinant human IL-2)
Number of subjects: 38
Study 30282975 — intervention group
Group type: EXPERIMENTAL
Intervention: H. haemolyticus identification
Number of subjects: 0
Study 30282975 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple in silico methods
Number of subjects: 0
Study 30282975 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylogenetic analysis of omp2 negative NTHi
Number of subjects: 0
Study 30282975 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of atypical group from isolates
Number of subjects: 0
Study 30283029 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg
Number of subjects: 99
Study 30283029 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 1.0 mg/kg
Number of subjects: 99
Study 30283029 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.1 mg/kg
Number of subjects: 99
Study 30283029 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0.045 mg/kg (active placebo)
Number of subjects: 99
Study 30283499 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg twice daily
Number of subjects: 0
Study 30283499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30283914 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard run-in weight-loss diet
Number of subjects: 234
Study 30283914 — intervention group
Group type: EXPERIMENTAL
Intervention: Different macronutrient diets for weight-loss maintenance
Number of subjects: 234
Study 30283914 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily meals preparation and service
Number of subjects: 234
Study 30284154 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (orally administered)
Number of subjects: 22
Study 30284224 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma GLP-1 concentrations measured on day 1 and day 4 after ad libitum feeding.
Number of subjects: 115
Study 30284224 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma GLP-1 on day 1
Number of subjects: 115
Study 30284224 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma GLP-1 concentrations prior to ad libitum food intake
Number of subjects: 115
Study 30284883 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention (FNI)
Number of subjects: 0
Study 30284883 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 0
Study 30284950 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0